Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 6—June 2019
Dispatch

New Delhi Metallo-β-Lactamase 5–Producing Klebsiella pneumoniae Sequence Type 258, Southwest China, 2017

Xin Zhang1, Weimin Wan1, Hua Yu1, Min Wang, Haifang Zhang, Jingnan Lv, Yi-Wei Tang, Barry N. Kreiswirth, Hong DuComments to Author , and Liang Chen
Author affiliations: Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Sichuan (X. Zhang, H. Yu); Memorial Sloan Kettering Cancer Center, New York, New York, USA (X. Zhang, Y.-W. Tang); The Second Affiliated Hospital of Soochow University, Suzhou, China (W. Wan, M. Wang, H. Zhang, J. Lv, H. Du); Rutgers University, Newark, New Jersey, USA (B.N. Kreiswirth, L. Chen)

Main Article

Table

Antimicrobial drug susceptibility of 3 bacterial isolates producing New Delhi metallo-β-lactamase 5, southwest China, 2017*

Characteristic
 Species, strain, and MIC, mg/L
Klebsiella pneumoniae, Kp2588
 Escherichia coli, Ec2551
 K. pneumoniae, Kp2573
Source Blood Urine Urine
Sequence type 258 48 258
Drug
Meropenem ≤0.25 ≥16 ≥16
Imipenem ≤0.25 ≥16 ≥16
Doripenem ≤0.12 ≥8 ≥8
Ertapenem ≤0.5 ≥8 ≥8
Ampicillin ≥32 ≥32 ≥32
Ticarcillin ≥128 ≥128 ≥128
Cephalothin ≥64 ≥64 ≥64
Cefazolin ≥64 ≥64 ≥64
Cefuroxime ≥64 ≥64 ≥64
Ceftazidime 16 ≥64 ≥64
Cefotaxime ≥64 ≥64 ≥64
Ceftriaxone ≥64 ≥64 ≥64
Cefpodoxime ≥8 ≥8 ≥8
Ceftizoxime ≤1 ≥64 ≥64
Cefepime 2 ≥64 ≥64
Cefotetan ≤4 ≥64 ≥64
Aztreonam ≥64 ≥64 ≥64
Piperacillin ≥128 ≥128 ≥128
Ampicillin/sulbactam ≥32/16 ≥32/16 ≥32/16
Amoxicillin/clavulanic acid 16/8 ≥32/16 ≥32/16
Piperacillin/tazobactam 64/4 ≥128/4 ≥128/4
Nitrofurantoin 256 ≤16 256
Gentamicin ≥16 ≥16 ≥16
Tobramycin ≥16 ≥16 ≥16
Amikacin 4 ≤2 4
Ciprofloxacin ≥4 ≥4 ≥4
Levofloxacin ≥8 ≥8 ≥8
Moxifloxacin ≥8 ≥8 ≥8
Trimethoprim/sulfamethoxazole ≥16/304 ≥16/304 ≥16/304
Nalidixic acid ≥32 ≥32 ≥32
Tetracycline ≥16 ≥16 ≥16
Tigecycline 2 ≤0.5 2

*Drug-resistant MICs are indicated in bold. Antimicrobial susceptibility testing was conducted by using the VITEK 2 system (bioMérieux, https://www.biomerieux.com).

Main Article

1These authors contributed equally to this article.

Page created: May 20, 2019
Page updated: May 20, 2019
Page reviewed: May 20, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external